Abstract 1755P
Background
Obesity is a strong risk factor for cancer, with more than 40,000 diagnosed cancers every year attributed to obesity. The role of nutrition in obesity-related cancers (ORC) needs to be better understood to develop tailored prevention strategies. The quality, rather than the quantity, of carbohydrate intake, seems to play a significant role. We investigated the relationship between dietary carbohydrate quality and risk of developing ORC in the "Seguimiento Universidad de Navarra” (SUN) Mediterranean cohort.
Methods
A total of 18,446 Spanish university graduates [mean age 38 years (SD 12), 61% women, mean BMI 23.5 kg/m2 (SD 3.5 kg/m2)], with no personal history of cancer, were followed-up for a median of 13.7 years. Baseline carbohydrate quality index (CQI) was assessed using 4 previously defined criteria: high dietary fibre intake, low glycemic index, high whole-grain: total-grain ratio and high solid carbohydrate: total carbohydrate ratio. Subjects were classified into tertiles according to their CQI score. Obesity-related incident cases were confirmed by an oncologist using medical records and by querying the National Death Index blindly to dietary exposures.
Results
During follow-up, 269 incident cases of obesity-related cancer were confirmed. A higher quality of carbohydrate intake, as measured by the baseline CQI, was associated with a lower risk of ORC with multivariable-adjusted hazard ratio (HR) for the upper (T3) versus the lowest tertile (T1) of 0.68 (95% confidence interval: 0.48, 0.97). Particularly, a higher dietary fibre intake was inversely associated with ORC, HR T3 vs. T1 = 0.58 (0.38, 0.89).
Conclusions
In this Mediterranean cohort, we observed a significant inverse association between a better global quality of carbohydrate intake and the risk of obesity-related cancers. This finding suggests that strategies for cancer prevention should emphasize the quality of carbohydrate intake, and particularly the dietary fibre intake.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Navarra.
Funding
Spanish Government-Instituto de Salud Carlos III, and the European Regional Development Fund (FEDER) (RD 06/0045, CIBER-OBN, Grants PI10/02658, PI10/02293, PI13/00615, PI14/01668, PI14/01798, PI14/01764, PI17/01795, PI20/00564 and G03/140), the Navarra Regional Government (27/2011, 45/2011, 122/2014), and the University of Navarra.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1890P - Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)
Presenter: Christopher Darr
Session: Poster session 23
1891P - Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma
Presenter: Renee Saliby
Session: Poster session 23
1892P - A pooled meta-analysis of salvage nivolumab/ipilimumab (N+I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
Presenter: Rana McKay
Session: Poster session 23
1895P - Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
Presenter: Sara Elena Rebuzzi
Session: Poster session 23
1896P - Clinical management and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with nivolumab+ipilimumab (N+I): A real-world study
Presenter: Tom Geldart
Session: Poster session 23
1897P - Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Presenter: Francesco Massari
Session: Poster session 23
1899P - Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)
Presenter: Georges Gebrael
Session: Poster session 23
1900P - Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the national cancer database (2004-2020)
Presenter: ALINA BASNET
Session: Poster session 23